Other than the original quoted article from Bioworld and Recce announcing that it is targeting the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) global initiative, which is offering a $1 billion reward for each new antibiotic approved, as well as increased R&D funding, I found the following articles and websites that mention these sort of rewards, there is also the Billions of potential revenue for any company that gets a new superbug antibiotic approved.
https://www.washingtonpost.com/opin...ory.html?noredirect=on&utm_term=.d5077c74e22e
http://www.ip-watch.org/2018/02/15/...d-2018-seeks-partners-antibacterial-research/
http://www.cidrap.umn.edu/news-perspective/2018/01/1-billion-reward-proposed-new-antibiotics
https://www.nature.com/articles/ja2017124
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746591/
Accelerated Approval for RECCE® 327, page-27
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.0¢ |
Change
-0.005(1.08%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 46.5¢ | 46.5¢ | 46.0¢ | $122.1K | 264.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 136398 | 45.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 144577 | 6 |
View Market Depth
| Last trade - 11.42am 11/07/2024 (20 minute delay) ? |
| RCE (ASX) Chart |